Cardiovascular Pharmacology: Open Access

Samer Ellahham

Publications

• Review Article
  Sacubitril/Valsartan in Management of Heart Failure: A Review of Safety, Efficacy and Cost-Effectiveness
  Author(s): Samer EllahhamSamer Ellahham
  
  Heart failure (HF) is a leading cause of mortality and morbidity across the globe. High prevalence, frequent hospitalization, longterm healthcare, absenteeism from work, and death upsurge the economic burden of the HF. For almost two decades, the angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), and beta-blockers (BBs) have remained the standard care of management for HF. But despite being efficacious and cost-effective theses standard treatment were unable reduce events of rehospitalization and improve quality of life for patients with HF. Recent innovative discovery of angiotensin receptor/neprilysin inhibitor (ARNI) therapy changed the entire outlook for management of HF. Sacubitril/Valsartan an ARNI proved out to be a revolutionary drug for patients of HF. Compared to other drug classes, Sacubitril/Valsartan combination therapy is more effi.. View More»
  DOI: 10.4172/2329-6607.1000250

  Abstract PDF